JP2015504299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504299A5 JP2015504299A5 JP2014538724A JP2014538724A JP2015504299A5 JP 2015504299 A5 JP2015504299 A5 JP 2015504299A5 JP 2014538724 A JP2014538724 A JP 2014538724A JP 2014538724 A JP2014538724 A JP 2014538724A JP 2015504299 A5 JP2015504299 A5 JP 2015504299A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion
- protein
- fusion protein
- ret
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 25
- 102000037865 fusion proteins Human genes 0.000 claims 25
- 230000004927 fusion Effects 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 210000000349 chromosome Anatomy 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 8
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 claims 7
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000003745 diagnosis Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000008707 rearrangement Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 229940127513 Fusion Protein Inhibitors Drugs 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229960001292 cabozantinib Drugs 0.000 claims 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 229940125874 fusion protein inhibitor Drugs 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553483P | 2011-10-31 | 2011-10-31 | |
| US61/553,483 | 2011-10-31 | ||
| US13/663,565 US10023855B2 (en) | 2011-10-31 | 2012-10-30 | Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker |
| US13/663,565 | 2012-10-30 | ||
| PCT/KR2012/009056 WO2013066047A1 (en) | 2011-10-31 | 2012-10-31 | Fusion protein comprising c-terminal domain of ret protein and use thereof as a diagnosing marker |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504299A JP2015504299A (ja) | 2015-02-12 |
| JP2015504299A5 true JP2015504299A5 (enExample) | 2015-12-03 |
| JP6389124B2 JP6389124B2 (ja) | 2018-09-12 |
Family
ID=48192340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538724A Active JP6389124B2 (ja) | 2011-10-31 | 2012-10-31 | Ｒｅｔ蛋白質のｃ−末端ドメインを含む融合蛋白質及びその診断マーカーとしての用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10023855B2 (enExample) |
| EP (1) | EP2773673B1 (enExample) |
| JP (1) | JP6389124B2 (enExample) |
| KR (2) | KR101625139B1 (enExample) |
| WO (1) | WO2013066047A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704126T3 (es) | 2011-08-23 | 2019-03-14 | Found Medicine Inc | Moléculas de fusión KIF5B-RET y usos de las mismas |
| EP2892532B1 (en) * | 2012-09-07 | 2019-02-13 | Exelixis, Inc. | Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma |
| US10668075B2 (en) | 2012-09-25 | 2020-06-02 | Chugai Seiyaku Kabushiki Kaisha | RET inhibitor |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| NZ742351A (en) | 2015-11-02 | 2023-03-31 | Blueprint Medicines Corp | Inhibitors of ret |
| UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| SG11202001212SA (en) * | 2017-08-21 | 2020-03-30 | Taiho Pharmaceutical Co Ltd | Fusion protein of dctn1 protein with ret protein |
| EP3773589B1 (en) | 2018-04-03 | 2023-11-01 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| CA3183728A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69736428T2 (de) | 1996-05-08 | 2007-08-30 | Biogen Idec Ma Inc., Cambridge | RET-LIGAND 3 (RetL3), UM NEURALES UND RENALES WACHSTUM ZU STIMULIEREN |
| US6797471B2 (en) | 2000-08-04 | 2004-09-28 | Board Of Regents, The University Of Texas System | Detection and diagnosis of smoking related cancers |
| WO2005044086A2 (en) | 2003-10-30 | 2005-05-19 | Tufts-New England Medical Center | Prenatal diagnosis using cell-free fetal dna in amniotic fluid |
| CA2624221A1 (en) | 2005-10-24 | 2007-05-03 | Takeda Pharmaceutical Company Limited | Preventives/remedies for cancer |
| EP2067039A2 (en) | 2006-09-12 | 2009-06-10 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research | Non-neuroendocrine cancer therapy |
| US20130137111A1 (en) | 2010-07-26 | 2013-05-30 | Astellas Pharma Inc. | Detection method of novel ret fusion |
| KR20140047138A (ko) | 2011-08-04 | 2014-04-21 | 도쿠리츠교세이호진 고쿠리츠간켄큐센터 | Ｋｉｆ5ｂ 유전자와 ｒｅｔ 유전자와의 융합 유전자, 및 당해 융합 유전자를 표적으로 한 암 치료의 유효성을 판정하는 방법 |
| ES2704126T3 (es) * | 2011-08-23 | 2019-03-14 | Found Medicine Inc | Moléculas de fusión KIF5B-RET y usos de las mismas |
-
2012
- 2012-10-30 US US13/663,565 patent/US10023855B2/en active Active
- 2012-10-31 EP EP12845116.8A patent/EP2773673B1/en active Active
- 2012-10-31 KR KR1020147013826A patent/KR101625139B1/ko active Active
- 2012-10-31 KR KR1020167010433A patent/KR101660235B1/ko active Active
- 2012-10-31 WO PCT/KR2012/009056 patent/WO2013066047A1/en not_active Ceased
- 2012-10-31 JP JP2014538724A patent/JP6389124B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Mycobacterium tuberculosis RbpA protein is a new type of transcriptional activator that stabilizes the σ A-containing RNA polymerase holoenzyme | |
| Malik et al. | Targeting the MLL complex in castration-resistant prostate cancer | |
| Dews et al. | Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster | |
| Ma et al. | The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications | |
| Lulli et al. | Mir-370-3p impairs glioblastoma stem-like cell malignancy regulating a complex interplay between HMGA2/HIF1A and the oncogenic long non-coding RNA (lncRNA) NEAT1 | |
| KR20160138494A (ko) | Fgfr 융합물 | |
| JP2019512014A (ja) | がん診断法および治療法におけるｐｉＲＮＡを使用する組成物および方法 | |
| CN111630166B (zh) | 条件性-siRNA及其在治疗心肌肥大中的用途 | |
| JP2015513529A5 (enExample) | ||
| JP2011511949A5 (enExample) | ||
| Fasanaro et al. | ROD1 is a seedless target gene of hypoxia-induced miR-210 | |
| JP2017516458A5 (enExample) | ||
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| US20210008070A1 (en) | Targeting minimal residual disease in cancer with cd36 antagonists | |
| Yang et al. | Circular RNA transcriptomic analysis of primary human brain microvascular endothelial cells infected with meningitic Escherichia coli | |
| US20250116034A1 (en) | Novel methods for rapid detection of immunogenic epitopes in biothreat agents and emerging pathogens for peptide vaccines and therapeutics | |
| KR20250021325A (ko) | 유전적 동인을 조절하기 위한 조성물 및 방법 | |
| Zhang et al. | MicroRNA‐146‐5p promotes pulmonary artery endothelial cell proliferation under hypoxic conditions through regulating USP3 | |
| RU2013103466A (ru) | Блокада сигнализации ccl18 через ccr6 как терапевтический способ лечения при фиброзных заболеваниях и раке | |
| Kumar et al. | t (4; 11) leukemias display addiction to MLL-AF4 but not to AF4-MLL | |
| KR20230088634A (ko) | 간암 특이적 바이오 마커 및 이의 용도 | |
| JP2014523736A5 (enExample) | ||
| JP2016211913A (ja) | 膀胱癌細胞のシスプラチン耐性マーカー及びその使用 | |
| Li et al. | NUP98‐p65 complex regulates DNA repair to maintain glioblastoma stem cells | |
| US20220218708A1 (en) | Methods for treating smarcb1 deficient cancer or pazopanib resistant cancer |